An Israeli biotech is looking to make its name in the jam-packed CD47 space. Is bifunctionality the answer?

Jerusalem’s KAHR Medical had been working on fusion proteins for autoimmune disorders for about 10 years, before “issues in development” spurred then-new CEO Yaron Pereg to change gears in 2017.

“We had done our gap analysis and thought, ‘This is a very cool technology and very interesting platform, why won’t...

Click to view original post